PULMATRIX, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
PULMATRIX, INC. (PULM) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $0 for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-15.
Discontinued › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2019-05-15
- PULMATRIX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2019-03-31 was $0.00.
- PULMATRIX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2018-12-31 was $0.00.
- PULMATRIX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2018-09-30 was $0.00.
- PULMATRIX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2018-06-30 was $0.00.
- PULMATRIX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2018 was $0.00.
- PULMATRIX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2017 was $0.00.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2019-03-31 | $0.00 10-Q · filed 2019-05-15 | $0.00 derived: sum of 2 quarters · filed 2019-05-15 | $0.00 derived: sum of 3 quarters · filed 2019-05-15 | $0.00 derived: sum of 4 quarters · filed 2019-05-15 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19 | $0.00 derived: sum of 2 quarters · filed 2019-02-19 | $0.00 derived: sum of 3 quarters · filed 2019-02-19 | $0.00 10-K · filed 2019-02-19 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $0.00 derived: sum of 2 quarters · filed 2018-11-14 | $0.00 10-Q · filed 2018-11-14 | $0.00 derived: sum of 4 quarters · filed 2018-11-14 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $0.00 10-Q · filed 2018-08-03 | $0.00 derived: sum of 3 quarters · filed 2018-08-03 | $0.00 derived: sum of 4 quarters · filed 2018-08-03 |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-11 | $0.00 derived: sum of 2 quarters · filed 2018-05-11 | $0.00 derived: sum of 3 quarters · filed 2018-05-11 | $0.00 derived: sum of 4 quarters · filed 2018-05-11 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | $0.00 derived: sum of 2 quarters · filed 2018-03-13 | $0.00 derived: sum of 3 quarters · filed 2018-03-13 | $0.00 10-K · filed 2018-03-13 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $0.00 derived: sum of 2 quarters · filed 2017-11-09 | $0.00 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | $0.00 10-Q · filed 2017-08-04 | ||
| 2017-03-31 | $0.00 10-Q · filed 2017-05-05 | |||
| 2015-06-30 | $531.00K 10-Q · filed 2015-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |